B38-CAP
B38-CAP Uses, Dosage, Side Effects, Food Interaction and all others data.
B38-CAP is structured as a carboxypeptidase and derived from Paenibacillus sp. The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels. It is being investigated for treating hypertension, myocardial fibrosis, and cardiac dysfunction.
| Trade Name | B38-CAP |
| Generic | Recombinant Bacterial ACE2 Receptors-like Enzyme |
| Recombinant Bacterial ACE2 Receptors-like Enzyme Other Names | B38-CAP, rbACE2 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
How B38-CAP works
Angiotensin Converting Enzyme 2 (ACE2) is a recently discovered enzyme that degrades Angiotensin II (known as Ang 1-8) into Ang1-7. Angiotensin II exerts actions like inflammation, ROS production, and vasoconstriction, and is implicated in acute respiratory distress syndrome (ARDS). Its conversion to Ang1-7 by ACE2 contrasts these actions as Ang1-7 promotes vasodilation, anti-inflammation, and NO release, attenuating tissue injury, including ARDS-associated injury. Additional administration of ACE2 by way of a recombinant protein is thought to aid in conversion of excessive Ang1-8 associated with ARDS into Ang1-7, and help reduce the depelatory effects of the renin-angiotensin system. This compound, as such, is being investigated for lung injury and ARDS associated with COVID-19.
Innovators Monograph
You find simplified version here B38-CAP
